NCT03931668Unknown早期 1 期
A Single Site, Randomized, Double-blind, Placebo-controlled, Incremental Phase I Clinical Trial: to Evaluate the Tolerance, PK and PD Effects of TPN-672 Maleate in Chinese Healthy Volunteers After Single Dose Administration.
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- ACR
研究概览
简要总结
This is a single-site, randomized, double-blind, placebo-controlled, incremental phase I clinical trial to evaluate preliminarily the tolerance, pharmacokinetics and pharmacodynamic effects of TPN672 maleate in Chinese healthy volunteers after single dose administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body weight > 50kg(male) or > 45kg(female), 19 <BMI<26 kg/m
- •Good communication with investigators, willingness and ability to abide by the lifestyle restrictions stipulated in clinical trial
- •Women or men within childbearing age do not have a fertility plan within 3 months after the end of the trial, and agree to adopt contraceptive measures approved (such as intrauterine device, condom, sperm killing gel, condom, uterine cap, etc.) throughout the clinical trial period.
- •Fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign the written informed consent, can complete the entire trial process according to the requirements of the trial.
排除标准
- •Investigator determined that there were diseases or functional disorders affecting clinical trials, including, but not limited to, central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system and blood system.
- •Mental illness or previous history of mental illness;
- •Have a history of ophthalmic diseases, such as abnormal color vision, retinitis pigmentosa, macular degeneration, etc.
- •Have a history of malignant tumors or other diseases that are not suitable for clinical trials;
- •Any surgical condition or condition that may significantly affect drug absorption, distribution, metabolism and excretion, or that may pose a hazard to the subjects participating in the study, such as history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcer, gastrointestinal bleeding, etc.
- •Those who are known to have a history of drug allergy, allergic disease or allergic constitution of the tested drug ingredients or similar drugs;
- •Smokers who smoked more than 10 cigarettes or the same amount of tobacco per day in the first year of screening;
- •Alcohol addiction within 1 year before screening, with an average weekly alcohol intake of more than 14 units (1 unit = 285 ml beer or 25 ml spirits or 150 ml wine) or positive alcohol breath test;
- •Those who had a history of drug abuse or drug abuse within 1 year before screening, or those who had positive urinary drug screening;
- •Physical examination, current medical history and vital signs were found to be abnormal by researchers and have clinical significance.
- •Resting pulse rate < 55/min or > 100/min; systolic pressure < 90 mmHg or > 140 mmHg, diastolic pressure < 60 mmHg or > 90 mmHg;
- •12-lead electrocardiogram (ECG) examination was found to be abnormal by investigator and had clinical significance; or the following ECG abnormalities occurred: PR interval > 220 ms, QRS complex wave duration > 120 ms, long QT syndrome (QTc > 450 ms);
- •Family history of sudden cardiac death (less than 40 years old);
- •Abnormal blood routine examination and urine routine examination have clinical significance.
- •Aspartate transferase (AST), alanine transferase (ALT), creatinine (Cr), urea nitrogen (BUN) exceeded the normal upper limit.
- •HBsAg, HCV-Ab, HIV-Ab and TRUST positive patients;
- •Pregnant or lactating women or male subjects whose spouses have child-rearing plans within three months;
- •Those who took any medicine within 2 weeks before admission, including prescription and non-prescription drugs;
- •Blood donation or blood loss (> 200 ml) within 3 months before admission, or a history of using blood products;
- •Participated in any clinical trials within 3 months before admission;
- •Those who had a history of operation within 3 months before admission, or who had not recovered from the operation, or who had anticipated operation plan during the trial period;
- •Do not agree to abide by the following conditions during the experiment: prohibit the use of tobacco, alcohol or caffeine-containing beverages, avoid strenuous exercise;
- •Personnel directly related to this clinical trial;
- •Investigator believes that other subjects are not suitable for the study.
研究组 & 干预措施
3mg single dose
Experimental
single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)
干预措施: TPN-672 (Drug)
0.125mg single dose
Experimental
single dose of TPN-672 0.125mg, 2 subjects
干预措施: TPN-672 (Drug)
0.25mg single dose
Experimental
single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)
干预措施: TPN-672 (Drug)
0.5mg single dose
Experimental
single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)
干预措施: TPN-672 (Drug)
1mg single dose
Experimental
single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)
干预措施: TPN-672 (Drug)
2mg single dose
Experimental
single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)
干预措施: TPN-672 (Drug)
4mg single dose
Experimental
single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)
干预措施: TPN-672 (Drug)
结局指标
主要结局
ACR
时间窗: 48 hours
Apparent Clearance Rate
ADV
时间窗: 48 hours
Apparent Distribution Volume
Adverse events
时间窗: 48 hours
Number of Subjects with adverse events during clinical trial
Cmax
时间窗: 48 hours
Maximum Plasma Concentration
AUC
时间窗: 48 hours
Area Under the Curve
Tmax
时间窗: 48 hours
Time to Cmax
T1/2
时间窗: 48 hours
Time of half life
次要结局
- prolactin(48 hours)
- temperature(48 hours)
- pulse rate(48 hours)
- QTc(48 hours)
- respiratory(48 hours)
- blood pressure(48 hours)
- electrocardiogram(ECG)(48 hours)
- Extrapyramidal symptoms(48 hours)
- Involuntary Movement(48 hours)
- Akathisia(48 hours)
- IL-6(48 hours)
- IL-4(48 hours)
- IL-1(48 hours)
- IL-2(48 hours)
- INF-gamma(48 hours)
- TNF-alpha(48 hours)
- 5-HT(48 hours)
- DA(48 hours)
- NE(48 hours)
- BDNF(48 hours)
- Glutamic acid(48 hours)
- GABA(48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271PneumoniaNCT02724085Tetraphase Pharmaceuticals, Inc.57
已完成
1 期
Safety Study of Oral BTA9881 to Treat RSV InfectionRespiratory Syncytial Virus InfectionsNCT00504907Biota Scientific Management Pty Ltd63
已完成
1 期
Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese ParticipantsAcute Bacterial Skin and Skin Structure Infection (ABSSSI)Prosthetic Joints Infection (PJI)NCT06394518TenNor Therapeutics Inc.32
终止
1 期
Single Dose Study of ANX005 in Healthy VolunteersSafety and Tolerability in Healthy VolunteersNCT03010046Annexon, Inc.27
已完成
1 期
A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM SubjectsHealthy SubjectsT2DM (Type 2 Diabetes Mellitus)ObesityNCT05943886Dongguan HEC Biopharmaceutical R&D Co., Ltd.164